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Abstract
Background: Known risk factors for death following a diagnosis of tuberculosis may not be applicable to current
U.S. cases. We evaluated the factors associated with all-cause mortality in patients with tuberculosis in Washington
State.
Methods: Using data from the Tuberculosis Information Management System of Washington State, we conducted
a cohort study of all residents diagnosed with tuberculosis from 1993 through 2005. Death from any cause was
ascertained through the Washington State Death Certificate Data Files. Proportional hazards models were used to
estimate the independent effect on all-cause mortality of demographic, clinical, and behavioral characteristics.
Results: During a median follow-up of 6 years in 3451 patients treated for tuberculosis, there were 417 deaths.
Mortality was independently associated with increasing age, male gender, HIV-coinfection, and U.S. birth. Within
1 year of tuberculosis diagnosis, treatment by a private provider and the use of directly observed therapy were also
independently associated with increased mortality. In addition, an interaction term of private provider times directly
observed therapy was also significantly associated with mortality.
Conclusions: We identified factors independently associated with increased all-cause mortality following a
diagnosis of tuberculosis. The associations between mortality and provider type should be evaluated with more
thorough adjustment for severity of illness, but suggest important directions for future research.
Background
There were over 1.7 million deaths due to tuberculosis
(TB) worldwide in 2007 with a global case-fatality of
19% [1,2]. The United States TB-specific case-fatality
has been estimated at 5% or less in recent years,
although a Baltimore-based study observed a case-fatal-
ity of 24% in sputum smear positive patients while on
treatment [2,3]. Studies evaluating risk factors for death
following a diagnosis of TB have typically focused on
specific patient populations (e.g. patients with multidrug
resistant-TB (MDR-TB), human immunodeficiency virus
(HIV)-coinfected patients, and patients enrolled in TB
treatment trials) [4-8]. Population-based studies have
identified a number of risk factors including HIV-coin-
fection, non-use of directly observed therapy (DOT),
care from a physician inexperienced with TB manage-
ment, drug resistance, and more than one site of TB
involvement as associated with death following a diag-
nosis of TB [7,9-11].
The applicability of these prior studies to the U.S. is
unknown as they were conducted outside of the United
States or during the TB resurgence of the 1990s. The
current characteristics of TB cases and TB control activ-
ities in the U.S. include increased use of DOT, increased
proportion of TB due to foreign born persons, and
greater delivery of TB treatment by public health
departments; Washington State has mirrored these
trends [12]. We performed a population-based study of
factors associated with mortality following a diagnosis of
TB in Washington State during a period of decreasing
TB incidence and stable treatment recommendations
[13]. We examined demographic, clinical and treatment
related characteristics associated with survival. Some of
the results of this study have been previously reported
in the form of an abstract [14].
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Study Population
The population in this cohort study consisted of all indi-
viduals diagnosed with active TB and reported to the
Washington State Department of Health Tuberculosis
Registry through the TB Information Management Sys-
tem (TIMS) during the period of January 1, 1993
through December 31, 2005. Tuberculosis is a reporta-
ble disease and the completeness of reporting in
Washington State is estimated to be nearly 100 percent
[15]. TB cases were defined according to the Centers for
Disease Control and Prevention (CDC) guidelines [16].
The Washington State Institutional Review Board
approved all study protocols and analyses.
Data Collection
We merged data from two sources: 1) TIMS, and 2) the
Washington State Death Certificate Data Files. The
Report of Verified Case of TB (RVCT) is the national
TB surveillance form produced by the CDC. Local pub-
lic health jurisdictions in Washington State are required
to complete and submit the RVCT to the State, where
information is entered into TIMS. Data on deaths in
Washington State and deaths of Washington State resi-
dents who died in other states are maintained in the
Death Certificate Files. We obtained death registry
information from January 1, 1993 to December 31,
2005. First and last names, as well as middle initials and
home address when available, were used in conjunction
with birth dates to link study subjects with data from
the death registry.
Person-time of cohort members began when anti-
tuberculosis treatment was started and ended on the
date of death or December 31, 2005, whichever came
first (information on the timing of the index culture was
available only for patients with pulmonary TB). We
decided on the variables for our model ap r i o r ibased
on known and potential risk factors, including: subject
characteristics (age, gender, race/ethnicity, HIV status,
U.S. birth, residence, substance use, income), disease
characteristics (site of TB disease, radiographic cavitary
disease, drug susceptibility, prior TB), and factors related
to treatment (provider type, use of DOT). These factors
were defined according to the RVCT [17]. Race and eth-
nicity were based on self-report. Provider type was
defined as a health department if outpatient care was
provided by a state or local health department. DOT
was defined as treatment ingestion observed by a health
care provider or other reliable person [17]. Variables
available for the analysis that were not defined by the
RVCT included recency of immigration to the United
States and median household income. The latter was
based on U.S. census data from 2000 using the subjects’
home zip code. Extrapulmonary TB was defined as dis-
ease in organs other than the lungs or pleura [7]. Pul-
monary TB with cavitation was defined as the presence
of cavitary lesions on chest radiograph. In order to
assess for temporal affects on survival, we included a
variable based on diagnosis in the first half or last half
of the study period ("year of diagnosis after 1999”).
In the bivariate and multivariable analyses, we made a
number of assumptions. Provider type was categorized
as private provider if TB care was never received from a
health department; otherwise care was categorized as a
health department. For example, a subject who was dis-
charged from a hospital and received treatment through
a health department would be categorized as having a
provider type of health department. Therapy type was
categorized as self-administered or “other” (including
DOT only or a combination of the two). Because of lim-
ited numbers, Pacific Islanders/Hawaiians were included
in the Asian category. If information was missing
regarding alcohol abuse, then patients were classified as
non-abusers. Similar assumptions were made for injec-
tion drug use, homelessness and institutional residence.
Subjects were considered HIV-positive only if they were
known to be seropositive. Patients without drug suscept-
ibility results were classified as having susceptible
isolates.
Statistical Analysis
We used Cox proportional hazards models to analyze
associations between candidate risk factors and survi-
val. The proportional hazards assumption was tested
using graphical inspection and tests for time trends of
Schoenfeld residuals. Variables that did not satisfy the
proportional hazards assumption (income, health care
provider type, and therapy type), were modelled after
being stratified by time. We also examined the signifi-
cance of two-way interactions between these time-
stratified variables, in addition to interactions between
age and sex. All of our pre-selected variables were
included in the final multivariable models based on
our initial hypotheses. To examine the effect of miss-
ing data and our assumptions on the model, we ana-
lyzed the data: 1) after excluding patients with missing
data, and 2) imputing values for missing data based on
frequencies observed for subjects with non-missing
data. After observing the relationship between provi-
der type and survival, we conducted a simulation
study to assess the potential impact of differential loss
to follow-up among subjects by provider type (see
additional file 1). Statistical analyses were performed
using Stata 10 (StataCorp, College Station, TX) and R
2.2.0 (R Foundation for Statistical Computing, Vienna,
Austria).
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During the 13-year study period, 3451 persons with
active TB were diagnosed in Washington State. The
median follow-up period was 5.9 years (interquartile
range [IQR]: 2.6-9.3). There were 417 deaths and cumu-
lative all-cause mortality at years 1 and 3 were 4.6%
(95% confidence interval [CI] 3.9-5.4) and 7.7% (CI 6.8-
8.8), respectively. Among HIV-coinfected patients the
one-year and three-year mortality were 10.5% (CI 6.4-
17.2) and 18.9% (CI 12.8-27.8), respectively.
The mean (± SD) age at the time of diagnosis was 45
(± 21) years. The date of initial sputum culture positivity
was reported in 1568 patients (68% of the pulmonary
TB cases), and anti-tuberculosis therapy was started less
than one week after collection of the initial sputum cul-
ture in 70%. The median time to treatment initiation in
these 1568 patients was 2 days after sputum collection
(IQR: 0-12). In the entire cohort, 85% of patients were
documented as completing therapy, 3% moved prior to
completion of treatment, 2% of patients were considered
lost and 1% refused treatment; among the remaining
patients, 5% died, 1% had “other” as the stop reason,
and information was missing in 3%.
Baseline characteristics for the cohort are in Table 1.
Most subjects were male (61%), foreign born (63%),
received DOT (61%), and were treated exclusively by a
public health department (54%). There was a low preva-
lence of known HIV-coinfection (5%). Except for resis-
tance to isoniazid (8%) and streptomycin (6.7%), there
was less than 2% prevalence of resistance to any single
drug; the prevalence of MDR-TB was 1%. Mortality was
lowest in females and in persons who were younger,
non-Caucasian, HIV-negative, and foreign born, and
also in persons without a prior history of TB or alcohol
abuse. The presence of both pulmonary and extrapul-
monary diseases was associated with an elevated death
rate, as was receipt of care through a private provider.
In the multivariable model that included all hypothe-
sized risk factors, we found that increasing age, male
gender, HIV-coinfection, treatment by a private health
care provider, the use of DOT, U.S. birth, and not being
a recent immigrant were independently associated with
increased mortality (Table 2). In developing our Cox
proportional hazards model, income, health care provi-
der type, and therapy type did not satisfy assumptions
of proportional hazards. However, after stratifying by
before or after the first year of follow-up, these variables
satisfied the proportional hazards assumption. Treat-
ment by a private health care provider (HR 5.1; 95% CI,
3.5-7.3) and use of DOT (HR 3.0; 95% CI, 1.9-4.5) were
associated with death only within one year of the diag-
nosis of TB; patients who survived one year were no
longer at increased risk of death based on these
variables. Income, after time stratification, was no longer
associated with survival. There were no significant inter-
actions between gender and age.
We evaluated our time stratified variables by model-
ling an interaction between health care provider type
and therapy type (Table 3). Different from our final
model, we found that receiving treatment from a private
health care provider was significantly associated with
decreased survival during the first year after a diagnosis
of TB regardless of therapy type, although the strength
of the association was greater if DOT was used (HR 8.5;
95% CI, 4.3-17.1) than if treatment was solely self-admi-
nistered (HR 2.2; 95% CI, 1.1-4.6).
TB-related deaths were 21% of all deaths and 39% of
the deaths that occurred within 12 months of starting
TB treatment. We assessed the effect on the model of
limiting mortality to TB-related deaths, defined as a TB-
related International Classification of Diseases code
listed under the multiple contributing causes of death
on the death certificate. Increasing age and HIV-coinfec-
tion were associated with a TB-related death; within one
year of TB treatment initiation, treatment by a private
health care provider and use of DOT were also asso-
ciated with a TB-related death (see additional file 2).
As differences in illness severity could introduce con-
founding if a subject’s death and TB diagnosis occurred
during the same hospitalization, we assessed the effects
on our model of excluding subjects who died within
30-days of a diagnosis of TB (n = 92). Although the HR
associated with treatment by a private health care provi-
der was attenuated, it remained elevated (HR 2.8,
1.7-4.6; see additional file 3). In order to assess the
impact of missing data and our assumptions on our
models, we repeated our analyses after: 1) excluding
patients with missing data, and 2) using imputed values
for missing data. There were no significant changes in
the observed associations compared to our final model
(results not shown).
We evaluated the association of sputum smear positiv-
ity and survival in patients with pulmonary TB. Neither
sputum smear positivity nor cavitation on chest radio-
graphs was found to be associated with survival (see
additional file 4). In patients with date of initial culture
collection, a delay in treatment (defined as treatment
initiation more than one week after sputum collection)
was not associated with death in bivariate or multivari-
able analysis.
Discussion
All-cause mortality in our study was predicted by older
age, HIV-coinfection, male g e n d e r ,U . S .b i r t h ,r e m o t e
immigration, care through a private health care provider
and the use of DOT. The association between care
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Characteristics N (%) (total = 3451) Person- years Mortality Rate 95% CI
Age, years: median (SD) 45 (21)
Gender
Female 1349 (39.1) 8183 12.3 10.2-15.0
Male 2102 (60.9) 12585 21.7 19.3-24.4
Race
Asian/Pacific Islander 1321 (38.2) 8159 10.3 8.3-12.8
Black 438 (12.7) 2316 13.4 9.4-19.0
Caucasian 982 (28.5) 5859 35.2 30.7-40.3
Latino 502 (14.5) 3097 7.8 5.2-11.6
Native American 179 (5.2) 1093 23.8 16.2-34.9
Unknown 29 (0.8) 204 14.7 4.7-45.6
HIV Status
Negative 1976 (57.2) 11753 11.7 9.9-13.8
Positive 166 (4.8) 905 44.2 32.4-60.2
Unknown 1309 (37.9) 8109 24.2 21.1-27.9
Major site of disease
Pulmonary/pleural 2652 (76.8) 16134 18.6 16.6-20.8
Lymphatic 425 (12.3) 2459 11.0 7.5-16.0
Bone-joint/GU/Peritoneal 206 (5.9) 1264 19.8 13.4-29.3
Miliary/Meningeal 92 (2.7) 515 33.0 20.5-53.1
Other 76 (2.2) 395 5.3 5.3-30.4
Site of disease
Pulmonary 2288 (66.3) 14229 18.3 16.2-20.6
Extrapulmonary 837 (24.2) 4887 13.3 10.4-17.0
Both 326 (9.4) 1652 29.7 22.4-39.3
Sputum Smear
Positive 1218 (35.3) 7150 20.6 17.5-24.2
Negative 1290 (37.4) 7426 16.3 13.6-19.5
Not applicable/missing 943 (27.3) 6191 17.1 14.2-20.7
Chest x-ray
Cavitary 626 (18.1) 3769 15.1 11.7-19.6
Non-cavitary 2237 (64.8) 13107 20.0 17.7-22.6
Unknown 588 (17.0) 3891 14.1 10.9-18.4
Isoniazid susceptibility
Resistant 281 (8.1) 1713 11.7 7.5-18.1
Susceptible 2529 (73.3) 14856 20.1 17.9-22.5
Unknown 641 (18.6) 4199 13.3 10.3-17.3
Streptomycin susceptibility
Resistant 241 (7.0) 1432 7.0 3.8-13.0
Susceptible 2530 (73.3) 15062 20.2 18.0-22.6
Unknown 680 (19.7) 4274 14.0 10.9-18.1
Previous TB
No 3168 (91.8) 19245 17.3 15.5-19.2
Yes 211 (6.1) 1210 27.3 19.4-38.4
Unknown 72 (2.1) 313 28.8 15.0-55.3
Excess alcohol use
No 2924 (84.7) 17558 16.3 14.6-18.4
Yes 346 (10.0) 1849 29.7 22.8-38.7
Unknown 181 (5.2) 1360 23.5 16.6-33.3
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sent only for the 12 month period following TB treat-
ment initiation.
Age, HIV-coinfection and male gender have been pre-
viously identified as risk factors for death in subjects
diagnosed with TB [7]. To our knowledge, U.S. birth,
and recent immigration have not been previously
described in relation to survival. U.S. birth has pre-
viously been reported as associated with relapse and
recurrence of TB [18]. In general, longer life expectancy
among immigrant groups has been observed in many
types of epidemiologic studies and may relate to a
“healthy immigrant effect” or healthier behaviors after
immigration compared to U.S -born individuals [19]. A
measure of disease severity, site of TB involvement (i.e.
miliary/meningeal), was associated with poorer survival
in bivariate analysis but did not remain so after adjust-
ment for HIV status.
We found an association of decreased survival and TB
treatment from a private provider during the first year
following treatment initiation for TB and this relation-
ship remained when evaluating only those patients that
experienced a TB related death. In our model, an indivi-
dual who received TB treatment from a private provider
and survived one year would no longer be at increased
risk of death based on this variable. An association
between increased physician experience in treating TB
and improved survival was recently reported in a Cana-
dian study [11]. Previous studies have observed that
management of TB by non-public health providers is
associated with inappropriate treatment regimens and
lower likelihood of cure. (24, 25) In our cohort, one
indicator of quality of TB care, documentation of spu-
tum culture conversion in patients with pulmonary TB
that completed treatment differed between health
department (93%) and private providers (67%); similarly
HIV status was assessed in 64% of patients treated by a
health department and 52% of patients treated by pri-
vate providers (p-value for both < 0.001).
DOT has been associated with improved likelihood of
completion of therapy, decreased relapse, and decreased
mortality [11,20-22]. However, a recent study from
Spain also found an association between the use of
DOT and increased mortality; the authors hypothesized
Table 1 Person-years, deaths and death rates by selected baseline characteristics (Continued)
Injection drug use
No 3090 (89.5) 19108 17.5 15.8-19.5
Yes 170 (4.9) 395 32.9 19.1-56.7
Unknown 191 (5.5) 1264 20.6 14.0-30.2
Correctional facility
No 3373 (97.7) 20240 18.1 16.3-20.0
Yes 93 (2.7) 397 15.1 6.8-33.6
Homeless
No 3073 (89.0) 18790 17.0 15.3-19.0
Yes 352 (10.2) 1788 28.0 21.2-36.9
Unknown 26 (0.8) 170 17.7 5.7-54.7
Long-term care
No 3358 (97.3) 20341 17.1 15.4-19.0
Yes 93 (2.7) 397 65.2 44.4-95.8
Therapy type
Directly observed therapy 2116 (61.3) 11794 19.2 16.8-21.8
Self-administered therapy 854 (24.7) 6596 17.7 14.8-21.3
Both 391 (11.3) 1977 11.6 7.7-17.5
Unknown 90 (2.6) 401 20.0 10.0-39.9
Health care provider type
Health department 1864 (54.0) 11727 10.3 8.6-12.3
Private 656 (19.0) 4081 32.6 27.5-38.6
Both 880 (25.5) 4681 24.4 20.3-29.3
Unknown 51 (1.5) 206 21.5 9.7-47.9
Immigration status
U.S.-born 1283 (37.2) 7546 34.5 30.5-38.9
Foreign-born 2168 (62.8)
U.S. resident ≥2 years 1208 (55.7) 14332 24.5 22.1-27.2
U.S. resident <2 years 960 (44.3) 6436 3.6 2.4-5.4
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cated patients [23]. We modelled an interaction between
health care provider type and therapy type to evaluate
our findings. The use of DOT by health departments in
this model was not significantly associated with differ-
ences in survival. However, we did find an association
between TB medical care by private physicians and
decreased survival regardless of the therapy type (i.e.
DOT or self-administered), although this association is
much stronger in patients who received DOT or combi-
nation therapy. A potential explanation for this may be
an indication bias where DOT is utilized by private pro-
viders based on increased severity of illness or decreased
social support. In bivariate analyses, we found increased
use of DOT among patients with smear-positive sputum
(84% vs. 78%, p-value 0.001), cavitary disease (83% vs.
78%, p-value 0.005), the homeless (96% vs. 72%, p-value
< 0.001) and lower incomes (p < 0.001).
There are limitations to our study. First, we were lim-
ited in our ability to address potential confounding, par-
ticularly related to differences in severity of illness. The
observed association between health care provider type
and survival could be confounded by differences in
severity of illness. We attempted to grade TB severity by
major organ site of involvement and the presence of
radiographic cavitations. In addition, we performed a
sensitivity analysis to address potential confounding due
to differences in severity of illness by excluding deaths
within 30 days of TB treatment initiation. Second, survi-
val follow-up was passive and our results could also be
influenced by incomplete ascertainment of deaths. A
disproportionate loss of subjects following the comple-
tion of treatment for TB who received their care
through a public health department could create the
appearance of decreased survival among subjects treated
by private health care providers. We simulated plausible
differences in follow-up to assess how this would induce
Table 2 All-cause mortality using proportional hazards
model including time stratified effects for income,
provider, and therapy
Variable HR 95% CI p
Age (year) 1.05 1.05, 1.06 <0.001
Male 1.5 1.2, 2.0 0.001
Race/ethnicity
Asian Reference ————— ————
Black 0.7 0.4, 1.2 0.22
Hispanic 0.9 0.5, 1.4 0.56
Native American 1.1 0.6, 2.0 0.70
White 1.2 0.8, 1.8 0.45
U.S. Born 1.7 1.2, 2.5 0.008
Foreign-born, U.S. resident <2
years*
0.4 0.3, 0.7 <0.001
HIV-positive† 4.2 2.8, 6.2 <0.001
Major site of Disease
Pulmonary Reference ————— ————
Lymphatic 1.0 0.6, 1.5 0.82
Bone or joint/Genitourinary/
Peritoneal
1.1 0.7, 1.7 0.62
Miliary/meningeal 1.3 0.8, 2.1 0.31
Other 0.7 0.3, 1.7 0.48
Radiographic cavitary disease 1.1 0.8, 1.6 0.44
Drug susceptibility||
INH susceptible 1.0 0.6, 1.7 0.99
Streptomycin susceptible 1.7 0.8, 3.7 0.18
Previous history of TB 1.0 0.7, 1.6 0.84
Alcohol abuse 1.2 0.8, 1.7 0.41
Intravenous drug use 1.4 0.8, 2.2 0.24
Homelessness 0.9 0.6, 1.2 0.41
Long-term care resident 1.1 0.7, 1.7 0.76
Income ($5000)
First year 0.9 0.9, 1.0 0.05
After first year 1.0 0.9, 1.0 0.25
Private provider only
Within 1 year of TB diagnosis 5.1 3.5, 7.3 <0.001
More than 1 year after TB
diagnosis
1.1 0.7, 1.5 0.77
Directly observed therapy
Within 1 year of TB diagnosis 3.0 1.9, 4.5 <0.001
More than 1 year after TB
diagnosis
1.0 0.7, 1.4 0.94
Year of diagnosis after 1999 1.0 0.8, 1.3 0.97
*Reference is immigration more than 2 years prior to TB diagnosis
†Reference category is HIV-negative or unknown
||Compared to INH and streptomycin susceptible isolates, respectively. Other
resistance patterns not included in the model due to limited numbers of
isolates.
Table 3 All-cause mortality using proportional hazards
model including directly observed therapy and provider
type interaction terms
Variable HR 95% CI
Age 1.05 1.05, 1.06
Male 1.5 1.2, 2.0
HIV-positive 4.2 2.9, 6.3
Provider type × DOT (≤1 year)*
Private provider, no DOT 2.2 1.1, 4.6
Health department, DOT 1.4 0.7, 2.8
Private provider, DOT 8.5 4.3, 17.1
Provider type × DOT (>1 year)*
Private provider, no DOT 1.1 0.7, 1.7
Health department, DOT 1.0 0.7, 1.5
Private provider, DOT 1.0 0.5, 2.0
Recent immigrant 0.4 0.3, 0.7
Not foreign born 1.7 1.2, 2.5
* Reference group is health department or both, no DOT
Except for interaction results, only statistically significant (p < 0.05) effects are
reported. The model was additionally adjusted for race, income, major site of
disease, INH susceptibility, streptomycin susceptibility, previous TB, excess
alcohol use, excess drug use, homelessness, in long term care, cavitary
disease, and year of diagnosis before or after 1999.
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that it is extremely unlikely that the hazard ratio we
observed was due in any large part to differential loss to
follow-up. (see additional file 1). Finally, our study was
based in a single state in which there is a low prevalence
of multidrug-resistant TB and may not apply to other
regions with higher prevalence of drug resistance.
Despite these limitations, we believe that this study has
important strengths. It is a population-based study that
reflects nationwide TB trends. Although we used all-
cause mortality as the primary outcome of our analysis,
similar to other studies of survival following a diagnosis
of TB, our observed associations persisted when we lim-
ited the outcome to TB related deaths [7,11,24]. Our
findings, particularly related to associations between pro-
vider type and survival, need to be verified in studies
where potential confounders can be assessed. If the find-
ings are verified, this would support further efforts to
identify mechanisms for the observed differences and
work to eliminate disparities in survival. Finally, it is
important to emphasize that our findings regarding the
use of DOT are likely due to differences in the types of
patients recommended for DOT in our study population.
Conclusions
In conclusion, we identified associations between
decreased survival in TB patients and age, male gender,
HIV-coinfection, US birth, remote immigration, DOT, and
TB treatment by a private health care provider. Although
it is important to acknowledge the potential for unmea-
sured confounding, our study suggests that additional stu-
dies are needed to assess associations between TB-related
physician experience and TB treatment outcomes.
Additional material
Additional file 1: Differential loss to follow-up simulation.A
simulation study to assess the potential impact of differential loss to
follow-up among subjects treated by private providers as compared to
health departments.
Additional file 2: Tuberculosis-related mortality using proportional
hazards model including time stratified effects for income,
provider, and therapy. We assessed the effect on the model of limiting
mortality to TB-related deaths, defined as a TB-related International
Classification of Diseases code listed under the multiple contributing
causes of death on the death certificate.
Additional file 3: Results of sensitivity analysis after excluding
subjects who died within the first 30 days. As differences in illness
severity could introduce confounding if a subject’s death and TB
diagnosis occurred during the same hospitalization, we assessed the
effects on our model of excluding subjects who died within 30-days of a
diagnosis of TB.
Additional file 4: Results of analysis evaluating an association
between sputum smear status and survival. We evaluated the
association of sputum smear positivity and survival in patients with
pulmonary TB.
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